- Conditions
- Epilepsy, Benign Neonatal
- Interventions
- Phenobarbital Sodium Injection
- Drug
- Lead sponsor
- NEMA Research, Inc.
- Industry
- Eligibility
- 34 Weeks to 44 Weeks
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 7
- States / cities
- Little Rock, Arkansas • Washington D.C., District of Columbia • Miami, Florida + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 79
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Brain Malformation, Neuronal Migration Disorder, Cognition Disorder, Epilepsy
- Interventions
- Not listed
- Lead sponsor
- Harvard University Faculty of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 3,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Epilepsy, Epilepsy, Generalized, Seizures
- Interventions
- Clobazam Low Dose, Clobazam Medium Dose, Clobazam High Dose, Placebo
- Drug
- Lead sponsor
- Lundbeck LLC
- Industry
- Eligibility
- 2 Years to 60 Years
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 34
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
- Conditions
- Developmental and Epileptic Encephalopathies, Epileptic Spasms, Genetic Epilepsy, Neonatal and Infant Epilepsy
- Interventions
- Ketogenic diet
- Drug
- Lead sponsor
- Heather Olson
- Other
- Eligibility
- 0 Days to 9 Months
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Epilepsy; Seizure, Neuromuscular Diseases, Brain Malformation, Intellectual Disability, Autism Spectrum Disorder, Hypotonia, Inborn Errors of Metabolism, Movement Disorders, Genetic Disease, Development Delay, Chromosome Abnormality, Hearing Loss, Dysmorphic Features, Skeletal Dysplasia, Congenital Abnormality, Microcephaly, Macrocephaly
- Interventions
- Pre-visit prep, usual care + exome seq
- Behavioral · Diagnostic Test
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 0 Years and older
- Enrollment
- 548 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 3
- States / cities
- Asheville, North Carolina • Chapel Hill, North Carolina • Greenville, North Carolina
- Conditions
- Hypoxic-Ischemic Encephalopathy, Brain Injury, Neonatal Seizure
- Interventions
- Neurologic examination
- Other
- Lead sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Other
- Eligibility
- Up to 6 Hours
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 4
- States / cities
- Detroit, Michigan • Columbus, Ohio • Providence, Rhode Island + 1 more
- Conditions
- Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
- Interventions
- TAK-935, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 12 more
- Conditions
- Developmental and Epileptic Encephalopathy
- Interventions
- LP352
- Drug
- Lead sponsor
- Longboard Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 66 Years
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 15 more
- Conditions
- Epilepsy, Epilepsy, Temporal Lobe, Seizures
- Interventions
- anteromesial temporal resection, antiepileptic drugs
- Procedure · Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 9 more
- Conditions
- Epilepsy, Lennox Gastaut Syndrome, Lennox-Gastaut Syndrome, Intractable, Seizures, Seizures, Generalized
- Interventions
- RNS System
- Device
- Lead sponsor
- NeuroPace
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 2 more
- Conditions
- Seizures, Lennox Gastaut Syndrome
- Interventions
- Carisbamate
- Drug
- Lead sponsor
- SK Life Science, Inc.
- Industry
- Eligibility
- 4 Years to 55 Years
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 22
- States / cities
- Palo Alto, California • Jacksonville, Florida • Orlando, Florida + 18 more
- Conditions
- Lennox Gastaut Syndrome
- Interventions
- Not listed
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- Up to 26 Years
- Enrollment
- 4,680 participants
- Timeline
- 2022 – 2025
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Ann Arbor, Michigan • St Louis, Missouri + 1 more
- Conditions
- Seizures, Encephalopathy
- Interventions
- EEG monitoring and treatment of EEG seizures
- Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 1 Hour to 72 Hours
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Tuberous Sclerosis Complex, Seizures
- Interventions
- GWP42003-P
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 1 Year to 65 Years
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Epilepsy
- Interventions
- retigabine/ezogabine
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years to 29 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Wellington, Florida • Memphis, Tennessee + 1 more
- Conditions
- Neonatal Seizure, Hypoxic-Ischemic Encephalopathy, Stroke, Intracranial Hemorrhage, Epilepsy, Gene Abnormality
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 8
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 4 more
- Conditions
- Neonatal Seizures
- Interventions
- levetiracetam
- Drug
- Lead sponsor
- Stephanie Merhar, MD
- Other
- Eligibility
- Up to 30 Days
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Lennox Gastaut Syndrome
- Interventions
- ZX008 0.2 or 0.8 mg/kg/day, Matching Placebo
- Drug
- Lead sponsor
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
- Industry
- Eligibility
- 2 Years to 35 Years
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 30
- States / cities
- Tucson, Arizona • Los Angeles, California • San Francisco, California + 26 more
- Conditions
- Neonatal Seizure, Hypoxic-Ischemic Encephalopathy, Stroke, Intracranial Hemorrhages, Epilepsy, Cerebral Palsy, Intellectual Disability
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 2 Years to 8 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 9
- States / cities
- San Francisco, California • Stanford, California • Washington D.C., District of Columbia + 5 more
- Conditions
- Tuberous Sclerosis Complex
- Interventions
- Basimglurant with crossover to Placebo, Placebo with crossover to Basimglurant
- Drug
- Lead sponsor
- Noema Pharma AG
- Industry
- Eligibility
- 5 Years to 30 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 6 more
- Conditions
- Hearing and Vision Loss
- Interventions
- Fitting algorithm
- Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Epilepsy, Lennox-Gastaut Syndrome
- Interventions
- GWP42003-P 20 mg/kg/day Dose, Placebo
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 55 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 17
- States / cities
- Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 14 more
- Conditions
- Seizures, Encephalopathy, Asphyxiated Newborn
- Interventions
- Not listed
- Lead sponsor
- Sharp HealthCare
- Other
- Eligibility
- 1 Day and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2015
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Lennox Gastaut Syndrome
- Interventions
- Clemizole HCl, Placebo
- Drug
- Lead sponsor
- Epygenix
- Industry
- Eligibility
- 2 Years to 55 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 24
- States / cities
- Little Rock, Arkansas • Orange, California • Wilmington, Delaware + 17 more